A Japanese government-funded study has revealed new opportunities for brands to develop functional foods and increase awareness among mineral-deficient consumers in Japan.
A total of 34.4% of Japanese female nursing professionals regularly consume supplements, especially those who are older, non-obese or pregnant, new data has shown.
Japan’s Foods with Function Claims (FFCs) exclusive market analysis, Asahi’s research on paraprobiotic benefits for alleviating menopause, and results from a government-funded survey in school children’s diet are some of the stories covered in this news...
Lonza’s insights on Japanese consumers’ mobility concerns, Mitsubishi’s nicotinamide mononucleotide (NNM) clinical findings, and Meiji’s infant formula business in Cambodia are the highlights of this round-up.
Consuming the paraprobiotic Lactobacillus gasseri CP2305 improves mild psychological symptoms and common vasomotor symptoms such as hot flashes unique to menopausal women, according to a Japanese study.
Nicotinamide mononucleotide (NNM) supplementation is safe and practical strategy to boost NAD+levels, which plays a crucial role in cell function, among healthy subjects.
This round-up looks at the new product launches in Japan, including Kao’s FFCs for mobility and cognitive health, GABA functional food innovation, and updates from Meiji and Kirin.
Japan has announced stricter labelling regulations for soybean milk and other soy-related beverages with the aim of preventing fraudulent or exaggerated claims and ensure fair competition between brands in the very competitive local market.
Kirin Brewery and Kirin Beverage have announced their respective business strategy for the year ahead, with the former focusing on strengthening its craft beer sales, and the latter on growing its immune care pillar.
Almost nine-out-of-10 people surveyed online in Japan have not heard of Health Support Pharmacies (HSPs), a new category of pharmacies that provide consultations on diet, nutrition, health foods and nursing care, alongside prescription medication.
The combination of two beta-glucans produced by Aureobasidium Pullulans (AFO-202 and N-163) strains along with standard treatment was shown to reduce inflammatory biomarkers in COVID-19 patients, compared to just the standard treatment alone.
The quality of clinical trials behind products under Japan’s Foods with Function Claims (FFCs) is undermined by a lack of proper protocols, such as the absence of trial registration and transparent study designs, says a new study.